Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Prescription Drug User Fee Program, 7186-7187 [2022-02617]
Download as PDF
7186
Federal Register / Vol. 87, No. 26 / Tuesday, February 8, 2022 / Notices
this draft guidance is primarily based on
FDA’s experience with ADCs for
oncology indications, the principles
discussed in this guidance are also
generally applicable to the development
of ADCs for other indications.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on ‘‘Clinical Pharmacology
Considerations for Antibody-Drug
Conjugates.’’ It does not establish any
rights for any person and is not binding
on FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
Dated: February 1, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
II. Paperwork Reduction Act of 1995
ACTION:
While this draft guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501–
3521) is not required for this guidance.
The previously approved collections of
information are subject to review by
OMB under the PRA. The collections of
information for submissions of
investigational new drug applications,
new drug applications, and biologic
license applications in 21 CFR parts
312, 314, and 601 have been approved
under OMB control numbers 0910–
0014, 0910–0001, and 0910–0338,
respectively. In addition, the
submission of prescription drug labeling
under 21 CFR 201.56 and 201.57 has
been approved under OMB control
number 0910–0572. The collections of
information in 21 CFR part 211 have
been approved under OMB control
number 0910–0139; and the collections
of information regarding good laboratory
practice in 21 CFR part 58 have been
approved under OMB control number
0910–0119.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics/biologics-guidances, https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents, or
https://www.regulations.gov.
VerDate Sep<11>2014
16:16 Feb 07, 2022
Jkt 256001
[FR Doc. 2022–02604 Filed 2–7–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2005–N–0101]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Prescription Drug
User Fee Program
AGENCY:
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(PRA).
Submit written comments
(including recommendations) on the
collection of information by March 10,
2022.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The OMB
control number for this information
collection is 0910–0297. Also include
the FDA docket number found in
brackets in the heading of this
document.
DATES:
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Prescription Drug User Fee Program
OMB Control Number 0910–0297—
Revision
This information collection supports
implementation of the Food and Drug
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
Administration Prescription Drug User
Fee Act (PDUFA) program. PDUFA was
enacted in 1992 and authorizes FDA to
collect fees from companies that
produce certain human drug and
biological products. Under the
prescription drug user fee provisions of
the Federal Food, Drug, and Cosmetic
Act (FD&C Act) (sections 735 and 736
(21 U.S.C. 379g and 379h)), we have the
authority to assess and collect user fees
for certain new drug applications
(NDAs) and new biologics license
applications (BLAs). Under this
authority, pharmaceutical companies
pay a fee for certain new NDAs and
BLAs submitted to FDA for review. We
have established a PDUFA page on our
website at https://www.fda.gov/
forindustry/userfees/
prescriptiondruguserfee/ that includes
resources and information regarding
PDUFA topics at FDA.
Because the submission of user fees
concurrently with applications is
required, review of an application by
FDA cannot begin until the fee is
submitted. To assist respondents in this
regard, we developed Form FDA 3397
entitled ‘‘PDUFA Cover Sheet.’’
Additional information and associated
instructions may be found on our
website at https://www.fda.gov/
industry/fda-user-fee-programs. The
cover sheet (Form FDA 3397) need not
be submitted for certain FDA-regulated
products, e.g., generic drugs, and whole
blood and blood components for
transfusion. The list of exempted
products is included under the
instructions to Form FDA 3397.
Relatedly, sections 735 and 736 of the
FD&C Act also provide for waiver,
reduction, refund, and reconsideration
requests. We developed the guidance
document entitled ‘‘Guidance for
Industry—Prescription Drug User Fee
Act Waivers, Reductions, and Refunds
for Drug and Biological Products,’’ and
Form FDA 3971 (Small Business Waiver
and Refund Request), which can be
found on our website at https://
www.fda.gov/media/131797/download.
We are revising the collection to
include our current commitment goals,
as set forth in the document ‘‘PDUFA
Reauthorization Performance Goals and
Procedures Fiscal Years 2018 Through
2022,’’ also found on our website at
https://www.fda.gov/media/99140/
download. PDUFA is currently
authorized through September 30, 2022,
with reauthorization activities currently
underway. The commitment goals
represent the product of FDA’s
discussions with the regulated industry
and public stakeholders, as mandated
by Congress. FDA is committed to
meeting these goals and to continuous
E:\FR\FM\08FEN1.SGM
08FEN1
7187
Federal Register / Vol. 87, No. 26 / Tuesday, February 8, 2022 / Notices
operational improvements associated
with PDUFA implementation. The
commitment goals provide for the
development and issuance of topicspecific guidance. We maintain a
searchable guidance database on our
website at https://www.fda.gov/
regulatory-information/search-fdaguidance-documents. In publishing the
respective notices of availability for
each guidance document, we include an
analysis under the PRA and invite
public comment on the associated
information collection
recommendations. In addition, all
Agency guidance documents are issued
in accordance with our good guidance
practice regulations in 21 CFR 10.115,
which provide for public comment at
any time.
In the Federal Register of November
30, 2021 (86 FR 67958), we published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
We estimate the burden of the
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Prescription drug user fee activity
Total
annual
responses
Average
burden per
response
Total hours
Sections 735 and 736 of the FD&C Act (PDUFA waivers,
not including small business waivers) ..............................
Section 736(d)(1)(C) of the FD&C Act and Form FDA
3971 (small business waivers) .........................................
Reconsideration Requests ...................................................
Appeal Requests ..................................................................
User Fee Cover Sheet Form FDA 3397 ..............................
112
1.68
189
17
3,213
37
6
1
174
1
1.67
1
1
37
10
1
174
2
24
12
0.5 (30
minutes)
74
240
12
87
Total ..............................................................................
........................
........................
411
........................
3626
1 There
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of Agency records,
we estimate that the number of initial
waiver requests submitted annually
(excluding small business waiver
requests under section 736(d)(1)(C)) of
the FD&C Act) will be 189, submitted by
112 different applicants; and that 37
respondents annually will each submit
a small business waiver request. We
have included in the burden estimate
the time for preparation and submission
of application fee waivers for small
businesses, including completion of
Form FDA 3971. Small businesses
requesting a waiver must submit
documentation to FDA, including the
number of their employees, as well as
information that the application is the
first human drug application, within the
meaning of the FD&C Act, to be
submitted to the Agency for approval.
We estimate receiving 10 requests for
reconsideration annually (including
small business waiver reconsiderations)
and assume the average burden for
preparing and submitting each request
is 24 hours. In addition, we estimate
receiving 1 request annually for appeal
of user fee waiver determination, and
assume the time needed to prepare an
appeal is 12 hours. We have included in
this estimate both the time needed to
prepare the request for appeal to the
Chief Scientist and User Fee Appeals
Officer within the Office of the
Commissioner, and the time needed to
create and send a copy of the request for
an appeal to the Director Division of
User Fee Management within the Office
VerDate Sep<11>2014
16:16 Feb 07, 2022
Jkt 256001
of Management at FDA’s Center for Drug
Evaluation and Research.
We assume 87 hours of burden for
completing and submitting Form FDA
3397 (Prescription Drug User Fee
Coversheet) for submission of a new
drug application or biologics license
application.
The information collection reflects an
overall increase since our last request
for OMB review and approval. We
attribute this to expected fluctuations in
submissions to the Agency.
Dated: February 2, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–02617 Filed 2–7–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3815]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Establishment
Registration and Device Listing for
Manufacturers and Importers of
Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
SUMMARY:
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on information
collection associated with establishment
registration and device listing for
manufacturers and importers of devices.
DATES: Submit either electronic or
written comments on the collection of
information by April 11, 2022.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 11,
2022. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of April 11, 2022. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
E:\FR\FM\08FEN1.SGM
08FEN1
Agencies
[Federal Register Volume 87, Number 26 (Tuesday, February 8, 2022)]
[Notices]
[Pages 7186-7187]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02617]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2005-N-0101]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Prescription Drug
User Fee Program
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing that a proposed collection of information has been submitted
to the Office of Management and Budget (OMB) for review and clearance
under the Paperwork Reduction Act of 1995 (PRA).
DATES: Submit written comments (including recommendations) on the
collection of information by March 10, 2022.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under Review--Open for Public
Comments'' or by using the search function. The OMB control number for
this information collection is 0910-0297. Also include the FDA docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Prescription Drug User Fee Program
OMB Control Number 0910-0297--Revision
This information collection supports implementation of the Food and
Drug Administration Prescription Drug User Fee Act (PDUFA) program.
PDUFA was enacted in 1992 and authorizes FDA to collect fees from
companies that produce certain human drug and biological products.
Under the prescription drug user fee provisions of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (sections 735 and 736 (21 U.S.C. 379g
and 379h)), we have the authority to assess and collect user fees for
certain new drug applications (NDAs) and new biologics license
applications (BLAs). Under this authority, pharmaceutical companies pay
a fee for certain new NDAs and BLAs submitted to FDA for review. We
have established a PDUFA page on our website at https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/ that includes resources
and information regarding PDUFA topics at FDA.
Because the submission of user fees concurrently with applications
is required, review of an application by FDA cannot begin until the fee
is submitted. To assist respondents in this regard, we developed Form
FDA 3397 entitled ``PDUFA Cover Sheet.'' Additional information and
associated instructions may be found on our website at https://www.fda.gov/industry/fda-user-fee-programs. The cover sheet (Form FDA
3397) need not be submitted for certain FDA-regulated products, e.g.,
generic drugs, and whole blood and blood components for transfusion.
The list of exempted products is included under the instructions to
Form FDA 3397. Relatedly, sections 735 and 736 of the FD&C Act also
provide for waiver, reduction, refund, and reconsideration requests. We
developed the guidance document entitled ``Guidance for Industry--
Prescription Drug User Fee Act Waivers, Reductions, and Refunds for
Drug and Biological Products,'' and Form FDA 3971 (Small Business
Waiver and Refund Request), which can be found on our website at
https://www.fda.gov/media/131797/download.
We are revising the collection to include our current commitment
goals, as set forth in the document ``PDUFA Reauthorization Performance
Goals and Procedures Fiscal Years 2018 Through 2022,'' also found on
our website at https://www.fda.gov/media/99140/download. PDUFA is
currently authorized through September 30, 2022, with reauthorization
activities currently underway. The commitment goals represent the
product of FDA's discussions with the regulated industry and public
stakeholders, as mandated by Congress. FDA is committed to meeting
these goals and to continuous
[[Page 7187]]
operational improvements associated with PDUFA implementation. The
commitment goals provide for the development and issuance of topic-
specific guidance. We maintain a searchable guidance database on our
website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents. In publishing the respective notices of
availability for each guidance document, we include an analysis under
the PRA and invite public comment on the associated information
collection recommendations. In addition, all Agency guidance documents
are issued in accordance with our good guidance practice regulations in
21 CFR 10.115, which provide for public comment at any time.
In the Federal Register of November 30, 2021 (86 FR 67958), we
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
We estimate the burden of the collection of information as follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Prescription drug user fee Number of responses per Total annual Average burden Total hours
activity respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Sections 735 and 736 of the FD&C 112 1.68 189 17 3,213
Act (PDUFA waivers, not
including small business
waivers).......................
Section 736(d)(1)(C) of the FD&C 37 1 37 2 74
Act and Form FDA 3971 (small
business waivers)..............
Reconsideration Requests........ 6 1.67 10 24 240
Appeal Requests................. 1 1 1 12 12
User Fee Cover Sheet Form FDA 174 1 174 0.5 (30 87
3397........................... minutes)
-------------------------------------------------------------------------------
Total....................... .............. .............. 411 .............. 3626
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Based on a review of Agency records, we estimate that the number of
initial waiver requests submitted annually (excluding small business
waiver requests under section 736(d)(1)(C)) of the FD&C Act) will be
189, submitted by 112 different applicants; and that 37 respondents
annually will each submit a small business waiver request. We have
included in the burden estimate the time for preparation and submission
of application fee waivers for small businesses, including completion
of Form FDA 3971. Small businesses requesting a waiver must submit
documentation to FDA, including the number of their employees, as well
as information that the application is the first human drug
application, within the meaning of the FD&C Act, to be submitted to the
Agency for approval.
We estimate receiving 10 requests for reconsideration annually
(including small business waiver reconsiderations) and assume the
average burden for preparing and submitting each request is 24 hours.
In addition, we estimate receiving 1 request annually for appeal of
user fee waiver determination, and assume the time needed to prepare an
appeal is 12 hours. We have included in this estimate both the time
needed to prepare the request for appeal to the Chief Scientist and
User Fee Appeals Officer within the Office of the Commissioner, and the
time needed to create and send a copy of the request for an appeal to
the Director Division of User Fee Management within the Office of
Management at FDA's Center for Drug Evaluation and Research.
We assume 87 hours of burden for completing and submitting Form FDA
3397 (Prescription Drug User Fee Coversheet) for submission of a new
drug application or biologics license application.
The information collection reflects an overall increase since our
last request for OMB review and approval. We attribute this to expected
fluctuations in submissions to the Agency.
Dated: February 2, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-02617 Filed 2-7-22; 8:45 am]
BILLING CODE 4164-01-P